Roche to Acquire Ignyta in $1.7B Deal

Roche has entered an agreement to acquire Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies, for $1.7 billion. The acquisition expands Roche’s oncology portfolio globally.

Ignyta will continue its operations in San Diego and will be responsible for the ongoing study of entrectinib, its most advanced cancer drug being studied in a range of solid tumor types. The company also has a portfolio of drugs in early stage development that use gene therapy to kill the underlying diseases that drive cancer tumor growth.
 
Ignyta employs an integrated "Rx/Dx" approach that combines precision medicines (Rx) and in-house molecular diagnostics (Dx) to both identify and target hard-to-treat cancers in hard-to-find patients.